Wednesday, August 15, 2018 6:45:32 PM
https://www.linkedin.com/in/alivia-rawls-24160b143/
"Alivia Rawls
Social Media Coordinator at KemPharm, Inc."
While I admit I could probably take a liking to her coordinating MY media, I just have to wonder about her qualifications:
"Experience
KemPharm, Inc. Social Media Coordinator
Dates Employed Mar 2017 – Present Employment Duration1 yr 6 mos
Location Celebration, Fl
Walt Disney World Internship
Dates Employed Aug 2016 – Jan 2017 Employment Duration 6 mos
Location Orlando, Florida
Education
University of Oklahoma
Degree NameBachelor of Science - BS Field Of Study Criminal Justice
Dates attended or expected graduation 2017 – 2018"
So she studied criminal justice for a year(?), spent 6 months as a Disney intern and NOW she's the "Social Media Coordinator" at Kempharm????
Hmmmmmmmmmm....is it just ME or does her BOYFRIEND:
https://www.facebook.com/photo.php?fbid=1864112083640113&set=a.114005575317448.17940.100001240170600&type=3&theater
...bear a rather striking resemblance to Kempharm's CEO:
https://pbs.twimg.com/profile_images/877584483066810368/-uR8VVSz_400x400.jpg
Ahhhhhhhh...probably just a COINCIDENCE, huh?
Recent KMPH News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2024 11:49:38 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/10/2024 08:23:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2024 11:46:20 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/09/2024 04:15:27 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/03/2024 08:17:44 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/03/2024 08:15:21 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/01/2024 09:27:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/30/2023 08:14:13 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM